Atezolizumab and Bevacizumab Attenuate Cisplatin Resistant Ovarian Cancer Cells Progression Synergistically via Suppressing Epithelial-Mesenchymal Transition

The AURELIA trial demonstrated that adding Bevacizumab to chemotherapy significantly improved progression-free survival (PFS) for platinum resistant recurrent ovarian cancer. Recently, immunotherapy also presented potential anti-tumor effects in several malignant solid tumors. This study aimed to in...

Descripción completa

Detalles Bibliográficos
Autores principales: Zhang, Lei, Chen, Ying, Li, Fangxuan, Bao, Lewen, Liu, Wenxin
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2019
Materias:
Immunology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6498972/
https://www.ncbi.nlm.nih.gov/pubmed/31105696
http://dx.doi.org/10.3389/fimmu.2019.00867

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6498972/
https://www.ncbi.nlm.nih.gov/pubmed/31105696
http://dx.doi.org/10.3389/fimmu.2019.00867

Ejemplares similares